Endogenous cannabinoids mediate hypotension after experimental myocardial infarction  by Wagner, Jens A et al.
EXPERIMENTAL STUDIES
Endogenous Cannabinoids Mediate
Hypotension After Experimental Myocardial Infarction
Jens A. Wagner, MD,* Kai Hu, MD,* Johann Bauersachs, MD,* Jan Karcher,* Martina Wiesler,*
Sravan K. Goparaju, PHD,† George Kunos, MD, PHD,† Georg Ertl, MD*
Wu¨rzburg, Germany; and Bethesda, Maryland
OBJECTIVES We sought to determine whether endocannabinoids influence hemodynamic variables in an
experimental models of acute myocardial infarction (MI).
BACKGROUND Hypotension and cardiogenic shock are common complications in acute MI. Cannabinoids
are strong vasodilators, and endocannabinoids are involved in hypotension in hemorrhagic
and septic shock.
METHODS The early effect of left coronary artery ligation on hemodynamic variables was measured in rats
pretreated with the selective cannabinoid1 receptor (CB1) antagonist SR141716A (herein
referred to as SR, 6.45 mol/kg body weight intravenously) or vehicle. Endocannabinoids
produced in monocytes and platelets were quantified by liquid chromatography/mass
spectrometry (LC/MS), and their effects on blood pressure and vascular reactivity were
determined.
RESULTS After MI, mean arterial pressure (MAP) dropped from 126  2 mm Hg to 76  3 mm Hg
in control rats, whereas the decline in blood pressure was smaller (from 121  3 mm Hg to
108  7 mm Hg, p  0.01) in rats pretreated with SR. SR increased the tachycardia that
follows MI (change [] in heart rate [HR]  107  21 beats/min vs. 49  9 beats/min
in control rats, p  0.05). The MI sizes were the same in control rats and SR-treated rats.
Circulating monocytes and platelets isolated 30 min after MI only decreased MAP when
injected into untreated rats (MAP20 5 mm Hg), but not in SR-pretreated rats. The
endocannabinoids anandamide and 2-arachidonyl glycerol were detected in monocytes and
platelets isolated after MI, but not in cells from sham rats. Survival rates at 2 h after MI were
70% for control rats and 36% for SR-treated rats (p 0.05). Endothelium-dependent arterial
relaxation was attenuated after MI (maximal relaxation: 44  3% [p  0.01] vs. 70  3% in
control rats) and further depressed by SR treatment (24  5%, p  0.01 vs. MI placebo).
CONCLUSIONS Cannabinoids generated in monocytes and platelets contribute to hypotension in acute MI.
Cannabinoid1 receptor blockade restores MAP but increases 2-h mortality, possibly by
impairing endothelial function. (J Am Coll Cardiol 2001;38:2048–54) © 2001 by the
American College of Cardiology
In the first few hours after myocardial infarction (MI),
cardiogenic shock characterized by inadequate cardiac out-
put, profound hypotension and systemic hypoperfusion is a
common clinical problem, as first described by Killip and
Kimball in 1967 (1). Although the in-hospital mortality rate
of patients with MI without heart failure was only 6%, the
mortality rate of those who developed cardiogenic shock
reached 81% (1). More recent data continue to show a grave
prognosis for cardiogenic shock, with in-hospital mortality
rates ranging from 43% to 73%. Even immediate coronary
revascularization had no effect on 30-day survival and only a
modest effect on six-month survival (2).
Beyond hemodynamic monitoring in specialized cardiac
care units, use of catecholamines and careful control of fluid
balance, the therapeutic palette includes mechanical support
by an intra-aortic balloon pump or left ventricular assist
devices as bridge therapy to heart transplantation. However,
a specific pharmacologic treatment to improve the poor
prognosis and to reverse the hypotension after MI has yet to
be introduced. Based on work using rodent models of MI,
a number of mechanisms have been suggested to contribute
to the development of congestive heart failure within weeks
to a few months after MI. Surprisingly, very little is known
about the possible mechanisms that account for the acute
hypotensive phase after MI.
Cannabinoids are best known for their psychoactive
properties, but they also influence cardiovascular variables
(for review, see [3]). The recently discovered endocannabi-
noids anandamide (4) and 2-arachidonyl glycerol (2-AG)
(5) act as natural ligands at specific cannabinoid1 (CB1) (6)
or CB2 (7) receptors. They mimic most of the biologic
effects of plant-derived and synthetic cannabinoids, includ-
ing cardiovascular actions.
We recently reported that in rat models of hemorrhagic
(8) and endotoxic shock (9), hypotension is prevented by
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pretreatment with the selective CB1 antagonist SR141716A
(herein referred to as SR). In addition, circulating mono-
cytes or platelets from rats in septic shock elicit CB1
receptor-mediated hypotension when injected into normal
rats, and these cells were found to generate anandamide and
2-AG (9). Intravenous (IV) injection of either anandamide
(10) or 2-AG (9) has been shown to elicit hypotension that
can be prevented by SR (11).
Therefore, in the present study, we investigated: 1)
whether endocannabinoids and their specific receptors may
mediate hypotension in cardiogenic shock; 2) whether early
endothelial dysfunction contributes to that mechanism; 3)
which cells may serve as a source of endocannabinoids; and
4) whether blockade of cannabinoid receptors restores blood
pressure and improves early mortality.
METHODS
Surgical procedures. All procedures were approved by the
Institutional Animal Care and Use Committee and were in
accordance with the “Position of the American Heart
Association on Research Animal Use,” adopted by the
Association in November 1984. Adult female Wistar rats
(weighing 275 to 300 g) were anesthetized with urethane
(0.7 g/kg IV plus 0.3 g/kg intraperitoneally) and heparin-
ized (500 IU/kg IV). Drugs or isolated blood cell prepara-
tions were injected through a polyethylene cannula in a
femoral vein. Heart rate (HR) and mean arterial pressure
(MAP) were monitored through a cannula inserted into the
femoral artery and connected to a pressure transducer and
physiograph. Coronary artery ligation was performed as
previously described (12). Rats received either SR or vehicle
(1:1:8 of ethanol/emulphor/saline; 0.2 ml) 15 min before
coronary ligation. The dose of SR used (6.45 mol/kg  3
mg/kg IV) produced near-maximal inhibition of the hypo-
tensive effect of anandamide (10), which is known to be
mediated by CB1 receptors (13). For survival studies, two
additional groups of rats underwent left coronary ligation
after pretreatment with vehicle or SR. The number of
surviving rats was established over a 2-h observation period.
The MI size was measured by triphenyltetrazolium chloride
staining. For all studies, only rats with infarct sizes 33%
were used.
Preparation of isolated blood cells. In rats not used for
hemodynamic measurements, 9 ml of blood was removed
30, 60 or 120 min after MI for isolation of platelets and
monocytes. Platelet-rich plasma was obtained by centrifu-
gation at 100  g for 15 min. The platelet-rich plasma was
further centrifuged at 800 g for 15 min, and the pellet was
resuspended in 0.2 ml of phosphate-buffered saline. The
mononuclear cell fraction was isolated from the remaining
blood, as described in detail elsewhere (14). Cells were
resuspended in 0.2 ml of phosphate-buffered saline and used
for biochemical analysis or transfusion experiments. For the
latter, both platelets and monocytes (	106) were injected
into recipient rats 15 min after SR (6.45 mol/kg IV) or
vehicle (control rats).
Measurement of anandamide and 2-AG. For liquid chro-
matography/mass spectrometry (LC/MS) analysis, mono-
cytes or platelets were isolated from 25 to 30 ml of pooled
normal or post-MI blood. The samples were spiked with 1
nmol of d-8-anandamide and 10 nmol d-8-2-AG as inter-
nal standards. Cells and medium were then extracted with
chloroform/methanol (2:1 vol/vol). The organic phase was
dried and resuspended in chloroform, to which ice-cold
acetone was added to precipitate proteins. After removal of
proteins by centrifugation, the organic phase was dried and
resuspended in methanol for analysis by LC/MS. Cell
extracts were fractionated by reverse-phase high-
performance LC on an ODS column (Supelcosil, 5 m,
4.6 mm 15 cm), using a mobile phase of methanol/water/
acetic acid (85:15:0.03 vol/vol/vol) at a flow rate of 1 ml/min.
This was followed by in-line MS analysis on a Micromass
Quattro II mass spectrometer equipped with an atmospheric
pressure, chemical ionization source. Two selected ions were
monitored simultaneously: selected on monitoring 387.2 for
d-8-2-AG ions as the internal standard, selected on monitor-
ing 379.2 for 2-AG ions, selected on monitoring 356.2 for
d-8-anandamide ions as the internal standard and selected on
monitoring 348.2 for anandamide ions.
Vascular reactivity studies. The descending thoracic aorta
was dissected after removal and cleaned. Three-millimeter
rings were mounted in an organ bath (Foehr Medical
Instruments, Seeheim, Germany) for isometric force mea-
surement. The rings were equilibrated for 30 min under a
rest tension of 2 g in oxygenated Krebs-Henseleit solution
containing diclofenac (1 mol/l), as detailed elsewhere (15).
The rings were repeatedly contracted with potassium chlo-
ride (100 mmol/l) until reproducible responses were ob-
tained. Thereafter, the rings were precontracted with phen-
ylephrine (0.3 to 1.0 mol/l) to 80% of maximal
contraction, and the relaxant response to the cumulative
application of acetylcholine and sodium nitroprusside
(SNP) was assessed.
Drugs and chemicals. SR141716A (N-[piperidin-1-yl]-5-
[4-chlorophenyl]1-1[2,4-dichlorophenyl]-4-methyl-1H-
pyrazol-3-carboxamide hydrogen chloride) was a gift from
Sanofi Recherche (Montpellier, France). Anandamide,
2-AG, d-8-anandamide and d-8-2-AG were provided by
Deva Biotech (Hatboro, Pennsylvania). Acetylcholine,
SNP, phenylephrine, triphenyltetrazolium chloride and
Histopaque-1077 were from Sigma.
Abbreviations and Acronyms
2-AG  2-arachidonyl glycerol
CB1  cannabinoid1 receptor
HR  heart rate
IV  intravenous
LC/MS  liquid chromatography/mass spectrometry
MAP  mean arterial pressure
MI  myocardial infarction
SNP  sodium nitroprusside
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Statistical analyses. The time-dependent effects of MI and
drug interventions on blood pressure, HR and vascular
reactivity were analyzed by analysis of variance, followed by
the Bonferroni post-hoc test. Differences between two
groups (SR or vehicle) or samples (with or without MI)
were analyzed by the Student unpaired t test. Survival data
were analyzed by the Fisher exact test.
RESULTS
There was no significant difference between the SR-
pretreated group (n  12) and the vehicle-treated control
group (n  16) regarding baseline MAP (121  3 mm Hg
vs. 126  2 mm Hg), HR (380  10 beats/min vs. 392 
11 beats/min), body weight (277 3 g vs. 284 9 g), heart
weight (1.11  0.04 g vs. 1.2  0.04 g) and infarct size
(39.9  3.6% vs. 38.3  3.7%).
CB1 receptor antagonist protects against post-MI hypo-
tension. Experimental MI caused immediate and long-
lasting hypotension and moderate tachycardia (Fig. 1). SR
almost completely prevented the drop in MAP and signif-
icantly enhanced the tachycardia. In agreement with earlier
findings (8,9), SR alone did not significantly change HR or
MAP.
SR141716A enhances early mortality after MI. Prompted
by the restoration of MAP by SR pretreatment, we also
tested its effect on mortality. The early survival rate was 70%
Figure 1. The effects of myocardial infarction on mean arterial pressure (A) and heart rate (B) in control rats (open circles; n  16) or
SR141716A-pretreated (solid circles, n  12) rats. SR141716A (6.45 mol/kg IV) was given 15 min before left coronary artery ligation, performed at 0
min. The vertical bars represent SEM. Significant differences (*p 0.05; §p 0.01; #p 0.001) from corresponding values in the absence of SR141716A.
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at 2 h after MI in untreated control rats, but only 36% in
rats pretreated with the CB1 receptor antagonist (p  0.05)
(Fig. 2).
MI induces the generation of cannabinoids in circulating
macrophages and platelets. Isolated monocytes and plate-
lets from rats with MI did not affect HR when injected into
vehicle-treated control rats or rats pretreated with SR (data
not shown). However, they caused gradually developing,
prolonged hypotension in control rats, whereas in rats
pretreated with SR, they caused enhanced MAP (Fig. 3).
Monocytes and platelets from control rats without MI did
not alter MAP or HR in recipients (data not shown).
Anandamide could be detected in samples from either
monocytes or platelets isolated after MI (Table 1), whereas
in samples from untreated control rats or sham-operated
rats, the anandamide content was below the limit of
detectability of 	0.01 pmol/ml (Table 1). Similar results
were obtained for 2-AG, which could be identified in
monocytes and platelets if isolated after MI, but not in cells
from control rats or sham-operated rats (Table 1).
Early endothelial dysfunction after MI is aggravated by
SR141716A. In post-MI rats, the vasodilatory response of
aortic rings to acetylcholine was attenuated, as compared
with that in sham-operated animals (Fig. 4A), whereas the
relaxation with the endothelium-independent vasodilator
SNP (Fig. 4B) was unchanged. Acetylcholine-induced re-
Figure 2. The effects of SR141716A (solid circles, n  25) on early survival after myocardial infarction; MI was performed at 0 min. The rats were treated
intravenously either with 6.45 mol/kg SR141716A or vehicle (open circles, n  20) 15 min before experimental myocardial infarction. *Significant
difference (p  0.05) from corresponding value in vehicle-treated rats.
Figure 3. Changes in blood pressure of recipient rats in response to circulating monocytes and platelets isolated from rats with myocardial infarction. See
Methods for details. Cells were injected into control (open circles, n  5) and SR141716A -pretreated (6.45 mol/kg IV; solid circles, n  4) rats at 0
min. Basal mean arterial pressure (MAP) and heart rate were 116 5 mm Hg and 402 19 beats/min before and 114 7 mm Hg and 383 36 beats/min
after SR141716A , respectively *Significant difference (p  0.05) from corresponding control value.
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laxation was reduced after pretreatment with SR in sham-
operated rats and further impaired in rats with MI, whereas
SNP-induced responses were not altered (Fig. 4).
DISCUSSION
The findings indicate that activated vascular CB1 receptors
contribute to severe hypotension after experimental MI in
rats. The endocannabinoids anandamide and 2-AG are
generated by circulating monocytes and platelets during
cardiogenic shock. The selective CB1 receptor antagonist
SR prevented post-MI hypotension, but aggravated early
endothelial dysfunction and worsened mortality.
The high mortality associated with cardiogenic shock
(1,2) and its resistance to current therapy justify the search
for underlying mechanisms, and our working hypothesis
was made plausible by growing evidence that endocannabi-
noids might be key players in the hemodynamic changes
that accompany certain forms of shock (8,9). Cannabinoids
are potent vasodilators and elicit hypotension and bradycar-
dia (9,10). Inhibition of these effects by CB1 receptor
antagonists and their absence in CB1 receptor knockout
mice implicate CB1 receptors (13). Activation of peripheral
CB1 receptors contributes to hypotension during hemor-
rhagic and septic shock (8,9). In both cases, the highly
selective CB1 receptor antagonist SR was able to restore
blood pressure to control levels, and monocyte- and
platelet-derived endocannabinoids have been identified as
possible paracrine mediators (8,9). Here we extend this
hypothesis to include cardiogenic shock.
Similarities of endocannabinoid action in hemorrhagic,
septic and cardiogenic shock. First, CB1 receptor antag-
onism prevents the hypotension that follows left coronary
artery ligation (Fig. 1A). Unlike nitric oxide, cannabinoids
are not tonically released, as indicated by the lack of change
in blood pressure after SR treatment in control animals.
Although the experimental MI model has been widely
used to induce chronic congestive heart failure, little is
known about the cellular/humoral factors that mediate
the early decrease in blood pressure after MI. The
observed 	50 mm Hg drop in MAP after MI is in
agreement with the scarce published data (16,17). However,
we noticed tachycardia rather than bradycardia (17), an
effect further enhanced by previous CB1 receptor blockade
(Fig. 1B). This might be explained by antagonism of the
known bradycardic effect of cannabinoids (10), which at-
tenuate the tachycardic effect of sympathetic activation
caused by the events associated with acute myocardial
hypoxia.
Second, preventing the MI-induced blood pressure de-
crease by CB1 receptor blockade had a detrimental effect on
early survival (Fig. 2), similar to hemorrhagic shock (8).
This is in agreement with the widely held view that
restoration of blood pressure alone after MI offers no benefit, as
Table 1. Production of Anandamide and 2-Arachidonyl
Glycerol in Platelets and Monocytes of Control, Sham or
Coronary-Ligated Myocardial Infarction Rats




Rats30 min 60 min 120 min
Anandamide, platelets 0.48  0.01 0.08  0.01  0.01
Anandamide, monocytes 1.55 0.15 0.38  0.01  0.01
2-AG, platelets 3.6 13.1 7.1  0.01  0.01
2-AG, monocytes 8.7 1.1 9.8  0.01 0.01
Data are pmol for anandamide and 2-arachidonyl glycerol (2-AG) (cells in 1 ml of
blood). Cells were isolated from blood pooled from three or four rats per group. Cells
from rats with myocardial infarction (MI) were obtained at 30, 60, or 120 min after
coronary artery ligation. In sham-operated and control rats, cells were obtained at 120
min only.
Figure 4. Relaxations induced by acetylcholine (A) and sodium nitroprus-
side (SNP) (B) in phenylephrine-preconstricted aortic rings from rats 2 h
after myocardial infarction (solid and open downward triangles), as
compared with sham-operated animals (solid and open circles). The rats
were treated with either vehicle (open circles and open downward
triangles) or SR141716A (6.45 mol/kg intravenous 15 min before
myocardial infarction (solid circles and solid downward triangles). The
results are expressed as the mean value  SEM from 8 to 12 separate
experiments. **p  0.01 for vehicle used in rats with myocardial infarction
vs. vehicle used in sham-operated rats vs. SR141716A used in rats with
myocardial infarction.
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illustrated by the persistent high mortality rate in patients
receiving high doses of catecholamines. In contrast, in hypo-
volemic and septic shock, pretreatment with the active
ingredient of the marijuana plant, 9-tetrahydrocannabinol,
improved survival (8,9). Shock-related hypotension triggers
compensatory sympathetic vasoconstriction that can compro-
mise the supply of oxygen to critical organs. Cannabinoids
have been shown to dilate isolated coronary (18) and cerebral
arteries (19) and recently have been shown to elicit strong
cerebral and coronary vasodilation in vivo (20). It is plausible
that endocannabinoid-induced vasodilation in cardiogenic
shock helps to maintain adequate tissue perfusion in the face of
decreased cardiac output and a compensatory increase in
sympathetic vasoconstrictor tone, and its removal by SR
pretreatment impairs survival.
As a further analogy with septic and hemorrhagic shock,
the same cells are shown to generate endocannabinoids in
cardiogenic shock. Monocytes and platelets from rats in
cardiogenic shock cause a SR-dependent drop in MAP in
normal recipient rats (Fig. 3). Furthermore, the same cells
are shown to synthesize anandamide and 2-AG when
isolated from rats in cardiogenic shock, but not from control
rats (Table 1). Monocytes and platelets are known to display
increased adherence to the vascular wall in septic (21) and
hemorrhagic (22) shock. Likewise, cannabinoids released
from adherent cells during cardiogenic shock may act as
paracrine activators at vascular CB1 receptors. This mech-
anism would greatly enhance their local concentration at
their vascular site of action, which could account for the
substantial vasodilatory effect. The discovery of monocyte
chemotactic and activating factor/monocyte chemoattrac-
tant protein-1 as an inflammatory mediator in patients with
acute MI underscores the involvement of monocytes in the
early stages of MI (23). As in septic shock, acute MI
enhances through inflammatory responses and systemic
hypoxia the release of monocyte-activating cytokines, such
as tumor necrosis factor-alpha (24), and monocyte inhibi-
tory cytokines, such as interleukin-10 (25). Also, cannabi-
noids themselves are able to alter the cytokine production of
macrophages, with as-yet unknown consequences on blood
pressure regulation (26).
We recently demonstrated that monocytes and platelets
generate endocannabinoids in experimental as well as
chronic human liver cirrhosis (27), which is often associated
with endotoxemia. Patients in cardiogenic shock are ex-
posed to bacterial endotoxin during bowel wall ischemia
(28). Elevated plasma levels of endotoxin, either as a
primary result of bacterial infection in septic shock or as a
secondary consequence of ischemic, low-output conditions,
may therefore be a common trigger for the production of
endocannabinoids, which, in turn, may contribute to the
associated hypotension.
Do endocannabinoids ameliorate early endothelial dys-
function after MI? Endothelial dysfunction contributing
to elevated peripheral resistance is a common problem in
congestive heart failure after MI (15). Here we show that in
rats with cardiogenic shock, endothelium-dependent but
not direct vasorelaxation is selectively attenuated (Fig. 4).
Similar observations have been made in hemorrhagic and
endotoxemic shock (29). In septic shock, SR caused
endothelium-dependent vasoconstriction in the mesenteric
artery, possibly due to antagonism of the vasodilatory effect
of a locally produced endogenous cannabinoid (30). Indeed,
there is evidence that 2-AG is generated in vascular endo-
thelial cells and contributes to the vasodilatory response to
acetylcholine (31,32), which may explain the observed
impairment of endothelial function after SR pretreatment in
both sham rats and those with MI (Fig. 4A). In rats in
cardiogenic shock, this further reduces the already impaired
endothelial function, which may contribute to the increased
mortality observed in rats with MI pretreated with SR.
Clinical implications. In the absence of rationally based
treatment regimens, the outcome of patients in cardiogenic
shock after MI remains abysmal. Therefore, the discovery of
new mechanisms could offer novel approaches for develop-
ing therapeutic strategies. For example, nitric oxide synthase
inhibitors are potent vasoconstrictors and are able to restore
blood pressure in shock situations. Nevertheless, their ef-
fectiveness as standard therapeutic agents has been disap-
pointing, although case reports and data obtained from
small patient groups receiving multiple treatment regimens
(33) may be encouraging.
The results of the present study show that endocannabi-
noids, a new class of neurohumoral vascular mediators, play
a role in the hemodynamic variables of cardiogenic shock.
Therefore, targeting their biosynthesis, specific receptors
and biologic degradation systems may become a new strat-
egy for the clinical management of cardiogenic shock.
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